- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- October 2024
- 200 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- March 2025
- 197 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- April 2023
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2023
- 189 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- March 2024
- 209 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- July 2023
- 118 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- April 2022
- 37 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Diabetic Gastroparesis Drug is a type of gastrointestinal drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to move food through the digestive tract. This condition is often seen in people with diabetes, and can cause nausea, vomiting, bloating, and abdominal pain. Diabetic Gastroparesis Drugs work by increasing the strength of the stomach muscles, allowing food to move through the digestive tract more easily. These drugs can also help reduce symptoms of nausea and vomiting. Common side effects of these drugs include constipation, diarrhea, and abdominal pain.
Some companies in the Diabetic Gastroparesis Drug market include Allergan, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
